Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for dermatological, oncology, and inflammatory diseases. The company operates within the biotechnology and life sciences industry, with a strategy centered on in-licensing and advancing early-stage drug candidates addressing unmet medical needs. Hoth Therapeutics does not currently generate product revenue and is primarily funded through equity financing to support research and development activities.
The company’s pipeline includes multiple product candidates targeting conditions such as atopic dermatitis, cutaneous T-cell lymphoma, acne, and cancer-related toxicities. Hoth’s strategic positioning emphasizes topical and localized therapies designed to reduce systemic side effects, which the company views as a potential competitive advantage. Hoth Therapeutics was incorporated in 2017 and became a publicly traded company through an initial public offering in 2020, trading on the Nasdaq Capital Market under the ticker symbol HOTH.
Business Operations
Hoth Therapeutics’ operations are organized around several development-stage therapeutic programs rather than revenue-generating business segments. Its key programs include HT-001, a topical formulation derived from a synthetic cannabidiol analog for inflammatory skin diseases; HT-KIT, a novel therapeutic targeting KIT-driven cancers; HT-003, a topical acne treatment; and HT-002, a formulation intended to prevent radiation-induced dermatitis in cancer patients. The company’s business model focuses on advancing these candidates through preclinical and early clinical development.
The company conducts research and development primarily through third-party contract research organizations and academic collaborators, rather than maintaining large internal laboratory infrastructure. Hoth does not currently market or sell products domestically or internationally and has no manufacturing facilities of its own. Its assets are primarily intellectual property rights, licenses, and clinical data associated with its therapeutic candidates.
Strategic Position & Investments
Hoth Therapeutics’ strategic direction centers on building value through the clinical advancement of a diversified pipeline of dermatology and oncology assets, with the long-term objective of partnering, licensing, or out-licensing programs to larger pharmaceutical companies. Growth initiatives include expanding indications for existing candidates and progressing assets into later-stage clinical trials when feasible.
The company’s pipeline has been built largely through licensing agreements with academic institutions and biotechnology partners rather than acquisitions of operating companies. Hoth has not disclosed any material acquisitions or controlling investments in other companies. Its emerging areas of focus include immune-mediated skin diseases and targeted oncology therapies, particularly those addressing treatment-limiting toxicities or genetically defined cancer subtypes.
Geographic Footprint
Hoth Therapeutics is headquartered in New York, United States, and its operations are primarily based in North America. The company does not maintain international offices or manufacturing sites and has limited direct operational presence outside the United States.
Despite its U.S.-centric footprint, Hoth’s clinical and preclinical activities may involve international research partners or service providers, depending on trial design and regulatory considerations. The company does not currently report material revenue, assets, or employees located outside the United States.
Leadership & Governance
Hoth Therapeutics is led by an executive team with experience in biotechnology development, capital markets, and healthcare operations. The company’s leadership emphasizes a capital-efficient development model, external collaboration, and disciplined advancement of early-stage therapeutic assets.
- Robb Knie – Chief Executive Officer
- David Grob – Chief Financial Officer
- Andrew F. Hill – President
- George W. Farmer – Chairman of the Board
The board of directors provides oversight of corporate strategy, governance, and risk management, with a focus on advancing shareholder value through clinical progress and strategic partnerships.